Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKB107
- Development stage
- Phase 1
- Lead developer
- Kelun-Biotech
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SKB107 is a radionuclide-drug conjugate (RDC) developed for the treatment of bone metastases in solid tumors. It is the first RDC clinical project from Sichuan Kelun-Biotech Biopharmaceutical and was jointly developed with Professor Chen Yue’s team at the Affiliated Hospital of Southwest Medical University. The drug utilizes a small molecule as its targeting ligand, which is combined with specialized conjugation technology, a chelator, and a therapeutic radionuclide. This design allows SKB107 to selectively target bone metastases, delivering cytotoxic radiation directly to tumor sites while minimizing damage to normal tissues. Compared to traditional external radiation therapy and conventional bone-modifying drugs, SKB107 aims for higher efficacy in killing tumor cells within bones and improved safety by reducing off-target effects[3][4][5][7].
- Other names
- 68Ga/177Lu-DOTA-IBA镥177-TBM-001
Beyond the preview
Go deeper on SKB107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKB107.